- Previous Close
0.2578 - Open
0.2500 - Bid --
- Ask --
- Day's Range
0.2206 - 0.2690 - 52 Week Range
0.1700 - 3.0000 - Volume
687,144 - Avg. Volume
8,101,555 - Market Cap (intraday)
7.759M - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
0.53 - EPS (TTM)
0.4800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Longevity Health Holdings, Inc. operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Corporation and changed its name to Longevity Health Holdings, Inc. in March 2025. Longevity Health Holdings, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
www.carmellcosmetics.com9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: XAGE
View MorePerformance Overview: XAGE
Trailing total returns as of 3/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XAGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XAGE
View MoreValuation Measures
Market Cap
7.71M
Enterprise Value
7.36M
Trailing P/E
0.53
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
171.54
Price/Book (mrq)
--
Enterprise Value/Revenue
223.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-6.39%
Return on Equity (ttm)
-115.65%
Revenue (ttm)
32.84k
Net Income Avi to Common (ttm)
-9.75M
Diluted EPS (ttm)
0.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
3.76M